High-throughput screening campaign identifies a small molecule agonist of the relaxin family peptide receptor 4

导出原文传递学术成果认领

作者 Guang-yao Lin ^[1] Lin Lin ^[2] Xiao-qing Cai ^[3] An-tao Dai ^[3] Yue Zhu ^[4] Jie Li ^[4] Qing Liu ^[3] De-hua Yang ^[4] Ross A.D.Bathgate ^[5] Ming-wei Wang ^[6] 学术成果认领

作者单位 The National Center for Drug Screening and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai 201203, China;School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China;University of Chinese Academy of Sciences, Beijing 100049, China ^[1] School of Pharmacy, Fudan University, Shanghai 201203, China ^[2] The National Center for Drug Screening and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai 201203, China ^[3] The National Center for Drug Screening and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai 201203, China;University of Chinese Academy of Sciences, Beijing 100049, China ^[4] Florey Institute of Neuroscience and Mental Health, Department of Biochemistry and Molecular Biology, The University of Melbourne, Parkville, VIC 3052, Australia ^[5] The National Center for Drug Screening and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai 201203, China;School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China;University of Chinese Academy of Sciences, Beijing 100049, China;School of Pharmacy, Fudan University, Shanghai 201203, China ^[6]

关键词 RXFP4 INSL5 high-throughput screening agonist JK1

栏目名称 Endocrine Pharmacology and Metabolic Disorders

发布时间 2020-11-10

基金项目

We are indebted to Ji Wu and Qiang Shen for technical assistance.This work was partially supported by grants from the National Natural Science Foundation of China 81872915 (MWW),81573479 (DHY),and 81773792 (DHY) the National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program" of China the National Key R&D Program of China 2018YFA0507000 (MWW) and the Novo Nordisk-CAS Research Fund Research at the Florey was supported by the Victorian Government's Operational Infrastructure Support Program.We are grateful to Tania Ferraro and Sharon Layfield for assistance with assays at the Florey.RADB is an NHMRC Senior Research Fellow.The funders had no role in the study design,data collect

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1
被引0
下载0

中国药理学报（英文版）

2020年41卷10期

1328-1336页

SCIMEDLINEISTICCSCDCABP

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

High-throughput screening campaign identifies a small molecule agonist of the relaxin family peptide receptor 4

中国药理学报（英文版）

相似文献

中国药理学报（英文版）

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

High-throughput screening campaign identifies a small molecule agonist of the relaxin family peptide receptor 4

中国药理学报（英文版）

相似文献

中国药理学报（英文版）

相关期刊

检索历史清除